Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,438.45 +276.90 (+0.44%) CMC Crypto 200
1,316.65 +39.67 (+3.11%)
BeyondSpring Inc. (BYSI)
After hours:
| Previous close | 2.2000 |
| Open | 2.1800 |
| Bid | 2.1900 x 100 |
| Ask | 2.3600 x 100 |
| Day's range | 2.1800 - 2.3000 |
| 52-week range | 0.6530 - 4.0000 |
| Volume | |
| Avg. volume | 228,219 |
| Market cap | 87.816M |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET. T
- GlobeNewswire
BeyondSpring Files 2023 Annual Report on Form 20-F
FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (“SEC”) on April 29, 2024. The annual report on Form 20-F, which contains the Company’s audited consolidated financial
- GlobeNewswire
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and Mechanism Data of BeyondSpring’s Lead Asset Plinabulin in Combination with PD-1 Inhibitor and Radiation in a Number of Immune Checkpoint Inhibitor Failed Cancers (Disease Control Rate >50%), Collaboration with MD Anderson - SEED Therapeutics (“SEED”), a BeyondSpring Subsidiary, Achieves Second and Third M
